Press release - 03/06/2022 Deep Learning helps improve gene therapies and antiviral drugs The nuclease Cas13b associated with the CRISPR gene scissors, which is an enzyme that degrades nucleic acids, has the potential to be used in the future in hereditary diseases to switch off unwanted genes. In the fight against infections, this nuclease is also being researched as an antiviral agent, as Cas13b can specifically intervene in the genetic material of viruses and render them harmless.https://www.gesundheitsindustrie-bw.de/en/article/press-release/deep-learning-helps-improve-gene-therapies-and-antiviral-drugs
Press release - 29/03/2022 Biocopy presents "ValidaTe" – A novel ultra-fast screening technology ValidaTe enables characterization of efficacy and safety of T-cell drug candidates in days rather than months. The breakthrough speed and unprecedented density of data processed can give partner companies a competitive advantage. New high-throughput microarray technology for label-free characterization of drug candidate interactions can significantly accelerate development in immune-oncology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/biocopy-presents-validate-novel-ultra-fast-screening-technology
Press release - 27/06/2019 Velabs Therapeutics Announces €3 Million Series B Financing to Advance its Functional Antibody Screening Programme Velabs Therapeutics GmbH, a leader in rapid screening of functional therapeutic antibodies, today announced the closing of a €3 million Series B financing round to advance its functional antibody screening programme and to strengthen its own pipeline of preclinical functional antibodies against diseases with poor treatment options. Further details of the financing round were not disclosed.https://www.gesundheitsindustrie-bw.de/en/article/press-release/velabs-therapeutics-announces-eur3-million-series-b-financing-advance-its-functional-antibody-screening-programme
Article - 26/10/2016 GeneWerk: precision analyses for humans Gene therapy approaches are increasingly being used for treating life-threatening diseases in humans. GeneWerk GmbH, a spin-off of the DKFZ and the NCT in Heidelberg, offers customised, high-resolution molecular and bioinformatic analyses that ensure the efficacy and safety of gene therapy and immunotherapy studies. https://www.gesundheitsindustrie-bw.de/en/article/news/genewerk-precision-analyses-for-humans
Article - 14/10/2015 High-throughput technologies and bioinformatics from a single source – the Quantitative Biology Center (QBiC) “Omics” is a current buzz word used to describe comprehensive investigations in many areas of the life sciences. In practice, omics refers to fields of scientific study that involve a huge number of experiments and even more data. Evaluating and managing all the data within a fixed period is a huge challenge for most researchers working on their own. It was to address these issues that the Quantitative Biology Center – QBiC for short – was…https://www.gesundheitsindustrie-bw.de/en/article/news/high-throughput-technologies-and-bioinformatics-from-a-single-source-the-quantitative-biology-center-qbic
Pharmaceutical research and life sciences profit from unique biosensor technology - 18/09/2015 Biametrics GmbH concludes financing round with 3.1 Million Euro Biametrics GmbH today announced the completion of their most recent financing round with €3.1 Million. Partners of the A Series Investment were LBBW Venture GmbH, MBG Mittelständische Beteiligungsgesellschaft BW, and KfW Bankengruppe. Together with seed investors HTGF and Seedfonds BW, they are aiming to accelerate the expansion of Biametrics’ bioanalytical business activities to an international level. The fresh capital will facilitate the…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biametrics-gmbh-concludes-financing-round-with-31-million-euro
Article - 31/08/2015 Company foundation in Baden-Württemberg: Günter Roth and the biomolecule copier Dr. Günter Roth is head of the “Microarray Copying“ research group at the Center for Biological Systems Analysis (ZBSA) at the University of Freiburg. Roth, who studied physics and biochemistry, has developed a biomolecule copier that he plans to use to establish his own company. The company will be called BioCopy, and the planned product lines, AptaSWIFT and immune2day, have already won numerous prizes for Roth and his team. In an interview with…https://www.gesundheitsindustrie-bw.de/en/article/news/company-foundation-in-baden-wuerttemberg-guenter-roth-and-the-biomolecule-copier
Article - 10/06/2014 Ribosome assembly as target for innovative antibiotics Although bacterial ribosomes are a popular target of common antibiotics, there are no drugs that specifically target ribosome assembly. To date, there is simply no screening method that would be suitable for assaying inhibitors of ribosomal subunit assembly. Prof. Dr. Elke Deuerling and Dr. Rainer Nikolay from the University of Konstanz have now achieved a breakthrough. They have developed a method that enables the high-throughput identification…https://www.gesundheitsindustrie-bw.de/en/article/news/ribosome-assembly-as-target-for-innovative-antibiotics
Article - 26/05/2014 HDC – state-of-the-art drug research at a location with a long-standing tradition Hit Discovery Constance GmbH (HDC) searches for new drug candidates on behalf of academic institutions and the pharmaceutical industry. Established in early 2014 on the Konstanz Campus (former Takeda/Nycomed/Altana research site), the joint venture organization offers high-throughput screening and compound management and storage services to support the transfer of academic research into the development of new medicines. With its high-throughput…https://www.gesundheitsindustrie-bw.de/en/article/news/hdc-state-of-the-art-drug-research-at-a-location-with-a-long-standing-tradition
Dossier - 28/04/2014 Data mining: new opportunities for medicine and public health Research and healthcare activities produce huge quantities of data that need to be presented in an understandable structure. This requires computer-assisted extraction of relevant data and the use of statistical methods. This process, known as data mining, enables the discovery of patterns in large data sets. Data mining methods are of particular importance in fields that use high-throughput methods, visualisation methods and telemedical…https://www.gesundheitsindustrie-bw.de/en/article/dossier/data-mining-new-opportunities-for-medicine-and-public-health
Article - 24/02/2014 Chemical tools for exploring cell division The cell cycle, consisting of interphase and mitosis, forms the basis for eukaryotic growth and reproduction. Numerous control and regulatory mechanisms guarantee that the separation and distribution of the chromosomes happens synchronously with the formation of the daughter cells. Amongst other things, the two daughter cells only form when the chromosomes are far enough apart from each other. Professor Dr. Thomas Mayer from the University of…https://www.gesundheitsindustrie-bw.de/en/article/news/chemical-tools-for-exploring-cell-division
Article - 17/02/2014 Personalised tumour diagnostics with high-throughput sequencing CeGaT GmbH Center for Genomics and Transcriptomics in Tübingen is one of the first organisations that have managed to combine human genetic diagnostics with high-throughput sequencing for the diagnosis of specific tumour variants. CeGat researchers have developed diagnostic panels that they use to study more than 550 tumour-relevant genes simultaneously. The identification of genetic changes provides a more detailed diagnosis of tumours and helps…https://www.gesundheitsindustrie-bw.de/en/article/news/personalised-tumour-diagnostics-with-high-throughput-sequencing
Article - 20/01/2014 Microarray copier – for copying DNA, RNA and protein arrays Dr. Günter Roth from the Centre for Biological Systems Analysis at the University of Freiburg is working on the development of a microarray copier that can almost at the push of a button copy arrays of any type of molecule DNA RNA and proteins from next-generation sequencing chips onto standard slides thereby combining the world of microarrays with the sequencing world. The approach has a huge application potential for the production of…https://www.gesundheitsindustrie-bw.de/en/article/news/microarray-copier-for-copying-dna-rna-and-protein-arrays
Press release - 15/01/2014 Hit Discovery Constance GmbH: a new hub for HTS and compound management Hit Discovery Constance GmbH (“HDC”), a new joint venture organisation between Lead Discovery Center (Dortmund/Germany), Centre for Drug Design and Discovery (CD3, KULeuven, Leuven/Belgium) and Axxam (Milan/Italy) has started its operation. The new company is based in Constance (Germany) and will make use of the already established equipment and know-how of the former Takeda/Nycomed/Altana screening and compound management facilities at the site.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hit-discovery-constance-gmbh-a-new-hub-for-hts-and-compound-management
Article - 09/09/2013 Karsten Borgwardt, a specialist in data mining The use of cutting-edge genomics, proteomics and metabolomics methods generates ever-increasing amounts of data in ever decreasing timescales. Special mathematical and computational methods are required for deducing relevant information from specific patterns. The data mining specialist Karsten Borgwardt from Tübingen is developing such methods for specific application in the life sciences. https://www.gesundheitsindustrie-bw.de/en/article/news/karsten-borgwardt-a-specialist-in-data-mining
Press release - 22/07/2013 BIOPRO Baden-Württemberg's international relations bring Heidelberg-based Medicyte GmbH in contact with new distribution partner BIOPRO Baden-Württembergs business development activities have led to the establishment of a new distribution partnership between Heidelberg-based Medicyte GmbH and Dutch Westburg BV. When BIOPRO searches for international partners for Baden-Württemberg companies the state agency often makes use of its international network partners and in this case BIOPROs contact with the Netherlands Business Support Office Stuttgart NBSO brought the desired…https://www.gesundheitsindustrie-bw.de/en/article/press-release/biopro-baden-wuerttemberg-s-international-relations-bring-heidelberg-based-medicyte-gmbh-in-contact
Article - 25/03/2013 IDP provides efficient help to address the flood of information The Institute of Data Analysis and Process Design IDP at the Zurich University of Applied Sciences ZHAW has developed intelligent software to analyse thousands of gene expression products simultaneously and automatically. This software considerably reduces the workload. The IDP has recently become a member of BioLAGO e.V. and specialises in statistical data analysis modelling and optimisation of processes and systems.https://www.gesundheitsindustrie-bw.de/en/article/news/idp-provides-efficient-help-to-address-the-flood-of-information
Dossier - 25/03/2013 Biotechnology goes automated Processes that previously required pipetting analysis and production to be carried out manually are increasingly now controlled by automated systems. However this has not necessarily involved a complete reinvention of the wheel instead automation systems used in the plant construction and mechanical engineering sectors are being adapted and optimised for application in the life sciences. https://www.gesundheitsindustrie-bw.de/en/article/dossier/biotechnology-goes-automated
Article - 02/04/2012 Looking for the molecular conductors of neuroembryogenesis Tissue development in areas such as the nervous system can be likened to the arrangement of various elements in a concert. Genetic control centres play a key role in coordinating which pieces of music are played in which order. These control centres regulate the expression of genes. A team of researchers led by Prof. Dr. Uwe Strähle from the Karlsruhe Institute of Technology KIT uses zebrafish to understand the gene networks that control…https://www.gesundheitsindustrie-bw.de/en/article/news/looking-for-the-molecular-conductors-of-neuroembryogenesis
Article - 10/01/2011 Review: What does the cell factory of the future look like? A symposium on “Cell Factories of the Future” was held at the Laupheim-based company Rentschler Biotechnologie on 14th and 15th October 2010. The event attracted around 70 scientists from academia and industry and will now take place every two years. The symposium focused on new biomanufacturing developments and technologies, and included lectures on (animal) cells, cell factories and the future of recombinant protein production. https://www.gesundheitsindustrie-bw.de/en/article/news/review-what-does-the-cell-factory-of-the-future-look-like
Dossier - 09/08/2010 Molecular design made to measure and the requirements Biomolecules such as peptides and nucleic acids can nowadays be synthesised relatively quickly and inexpensively. In addition, great progress has been made in the development of methods enabling the directed mutagenesis in microorganisms. These two developments have boosted the design of new, and the reorganisation of known, molecules. Moreover, these help in the utilisation of certain molecule functions in research and in the industrial…https://www.gesundheitsindustrie-bw.de/en/article/dossier/molecular-design-made-to-measure-and-the-requirements
Article - 10/05/2010 CeGaT: DNA and RNA sequencing specialist Sequencing service providers are facing new challenges due to the enormous technological progress made in this field. The market requires technically feasible solutions reliable and rapid sequence analyses in which entire genomes can be analysed within a couple of days or weeks. This can only be achieved with state-of-the-art high-throughput technologies. Tübingen-based CeGaT GmbH has been offering DNA and RNA sequencing using state-of-the-art…https://www.gesundheitsindustrie-bw.de/en/article/news/cegat-dna-and-rna-sequencing-specialist
Press release - 30/11/2009 Boehringer Ingelheim announces record productivities for CHO cells using the BI-HEX technology platform A team of Boehringer Ingelheim scientists reports another milestone in the development of the BI-HEX® technology platform. A record productivity of more than 100 picogramms per cell per day was achieved in inoculum and fed-batch cultures of BI-HEX® Chinese hamster ovary (CHO) cell lines expressing a therapeutic monoclonal antibody. https://www.gesundheitsindustrie-bw.de/en/article/press-release/boehringer-ingelheim-announces-record-productivities-for-cho-cells-using-the-bi-hex-technology-platf
Press release - 21/10/2009 GRAFFINITY enters into drug discovery research collaboration with GENENTECH HEIDELBERG, October 15, 2009 — Graffinity Pharmaceuticals GmbH announced today that it has entered into a drug discovery research collaboration with Genentech, Inc, a wholly-owned member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY). With this collaboration Genentech will gain access to Graffinity’s proprietary, fragment-based drug discovery technology.https://www.gesundheitsindustrie-bw.de/en/article/press-release/graffinity-enters-into-drug-discovery-research-collaboration-with-genentech
Article - 10/06/2009 Colleagues who became customers Should they work with a long-standing cooperation partner or should they set up another company that was the decision faced by the staff of the Discovery-IT department of Nycomed formerly ALTANA Pharma in the spring of 2007.https://www.gesundheitsindustrie-bw.de/en/article/news/colleagues-who-became-customers